Last reviewed · How we verify
placebo and pregabalin
Pregabalin is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA) and acts as a GABA receptor agonist.
Pregabalin is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA) and acts as a GABA receptor agonist. Used for Neuropathic pain, Fibromyalgia.
At a glance
| Generic name | placebo and pregabalin |
|---|---|
| Also known as | Lyrica |
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | GABA receptor agonist |
| Target | alpha2-delta subunit of voltage-gated calcium channels |
| Modality | Small molecule |
| Therapeutic area | Pain, Anxiety |
| Phase | Phase 3 |
Mechanism of action
Pregabalin binds to a specific site on the alpha2-delta subunit of voltage-gated calcium channels, which are involved in the release of various neurotransmitters. This binding reduces the release of excitatory neurotransmitters, leading to a decrease in neuronal excitability and a reduction in pain and anxiety symptoms.
Approved indications
- Neuropathic pain
- Fibromyalgia
Common side effects
- Dizziness
- Somnolence
- Headache
Key clinical trials
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia (NA)
- Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy (PHASE2)
- Effect of Pregabalin on the Postoperative Analgesia in RFA of Focal Lesions in the Liver (PHASE4)
- A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain (PHASE1)
- Adding Amantadine or Duloxetine to Pregabalin on Occurrence of Post Mastectomy Pain Syndrome (NA)
- Pregabalin Plus Lofexidine for the Outpatient Treatment of Opioid Withdrawal (PHASE2)
- The Effects of Preemptive Multimodal Analgesic on Endodontic Pain Following Root Canal Therapy. (EARLY_PHASE1)
- Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: